Gianfranco Caselli

USPTO Granted Patents = 26 (Patent Applications = 6)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 14 (Patent Applications = 12)

Average Co-Inventor Count = 5.7

ph-index = 3

Forward Citations = 31(Granted Patents)

Location History:

L'Aquila, IT (2000 - 2012)
Milan, IT (1997 - 2023)

Company Filing History:

Rottapharm Biotech S.r.l.

patents

4. 3 out of 48

Dompe' Farmaceutici S.p.a.

patents

5. 1 out of 14

Dompe Pha.r.ma S.p.a.

patents

Years Active: 1997-2025

Loading Chart...

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12433875 - (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or its salt also in polymorphic form a for use in the prevention of heterotopic ossification (2025-10-07),

2. 11590114 - Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumours (2023-02-28),

3. 10125121 - FYN kinase inhibitors (2018-11-13),

4. 9631029 - Anti-ADAMTS-5 antibody, derivatives and uses thereof (2017-04-25),

5. 9493402 - Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells (2016-11-15),

6. 9365654 - Anti-TrkA antibodies, derivatives and uses thereof (2016-06-14),

7. 8633208 - 6-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor ligands (2014-01-21),

8. 8420634 - Amidine, thiourea and guanidine derivatives of 2-aminobenzothiazoles and aminobenzothiazines for their use as pharmacological agents for the treatment of neurodegenerative pathologies (2013-04-16),

9. 8372866 - 2-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related pain (2013-02-12),

10. 8288368 - Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells (2012-10-16),

11. 8258185 - Use of neboglamine in the treatment of toxicodependency (2012-09-04),

12. 8193353 - 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents (2012-06-05),

13. 7994181 - 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents (2011-08-09),

14. 7968558 - Amidine derivatives of 2-heteroaryl-quinazolines and quinolines; potent analgesics and anti-inflammatory agents (2011-06-28),

15. 7906551 - 3-substituted-1,5-diarly-2-alkyl-pyrroles highly selective and orally effective COX-2 inhibitors (2011-03-15),

Title: Gianfranco Caselli: Innovator in Pharmaceutical Compounds

Introduction

Gianfranco Caselli is a prominent inventor based in Milan, Italy, recognized for his substantial contributions to the pharmaceutical industry. With an impressive portfolio of 25 patents, he has focused on developing innovative treatments that target various medical conditions, particularly tumors and arthritis.

Latest Patents

Among his latest inventions is a groundbreaking pharmaceutical combination that pairs an EP4 antagonist with immune checkpoint inhibitors for tumor treatment. This combination includes a specific EP4 antagonist compound and describes a unique polymorphic form of the sodium salt, which is detailed through its powder XRD spectrum. Additionally, Caselli has developed selective FYN kinase inhibitors targeting pain and arthritis, including osteoarthritis and rheumatoid arthritis, demonstrating his commitment to advancing therapeutic options in these critical healthcare areas.

Career Highlights

Throughout his career, Gianfranco Caselli has worked with notable companies such as Rottapharm Spa and Dompe S.p.a., where he contributed to the research and development of various innovative pharmaceutical products. His work has significantly impacted the treatment landscape for conditions that often have limited therapeutic options.

Collaborations

Caselli has collaborated with esteemed professionals in the field, including Lucio C. Rovati and Antonio Giordani. These partnerships have enabled the fusion of diverse expertise, fostering the generation of cutting-edge innovations in pharmaceuticals.

Conclusion

Gianfranco Caselli's contributions to the pharmaceutical industry underscore the importance of innovation in developing effective treatments for challenging medical conditions. His dedication to research and development continues to inspire advancements that may improve patient outcomes globally.

This text is generated by artificial intelligence and may not be accurate.